UB Paderborn / Katalog / Suche / in CDI

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Volltextzugriff (PDF)

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

The Journal of pharmacology and experimental therapeutics, 2017-02, Vol.360 (2), p.346

2017

Volltextzugriff (PDF)

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Annals of oncology, 2018-10, Vol.29, p.viii320-viii321

2018

Volltextzugriff (PDF)

Understanding Mid For Micturition Frequency, A Pivotal Endpoint For Oab Studies

Value in health, 2014-05, Vol.17 (3), p.A294-A294

2014

Volltextzugriff (PDF)

Perioperative use of etoricoxib in patients undergoing total abdominal hysterectomy

The journal of pain, 2011, Vol.12 (4), p.P64-P64

2011

Volltextzugriff (PDF)

P83.02 Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S653-S654

2021

Volltextzugriff (PDF)

Once Daily Vibegron Improves Quality of Life Measures in Patients with Overactive Bladder

Value in health, 2018-05, Vol.21, p.S267-S268

2018

Volltextzugriff (PDF)

PUK17 - Once Daily Vibegron Improves Quality of Life Measures in Patients with Overactive Bladder

Value in health, 2018-05, Vol.21, p.S267-S268

2018

Volltextzugriff (PDF)

T624 RELATIVE TREATMENT EFFECTS OF PERIOPERATIVE ETORICOXIB ON PAIN AT REST AND UPON MOVEMENT FOLLOWING ABDOMINAL HYSTERECTOMY

European journal of pain supplements, 2011-09, Vol.5 (1), p.87-88

2011

Volltextzugriff (PDF)

PUK27 - Understanding Mid For Micturition Frequency, A Pivotal Endpoint For Oab Studies

Value in health, 2014-05, Vol.17 (3), p.A294-A294

2014

Volltextzugriff (PDF)

Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

Annals of oncology, 2017-09, Vol.28, p.v301-v301

2017

Volltextzugriff (PDF)

Bladder dysfunction in mice with experimental autoimmune encephalomyelitis

Journal of neuroimmunology, 2008-10, Vol.203 (1), p.58-63

2008

Volltextzugriff (PDF)

Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study

Contraception (Stoneham), 2016-10, Vol.94 (4), p.362-365

2016

Volltextzugriff (PDF)

989TiPKEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

988TiPKEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

990TiPPhase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

919PThree-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

864OPembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Results of a Simplified Technique for Buried Penis Repair

The Journal of urology, 2004-02, Vol.171 (2), p.826-828

2004

Volltextzugriff (PDF)

901PImpact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Pelvic hematoma as a cause of bladder perforation and gross hematuria

Urology (Ridgewood, N.J.), 2004-11, Vol.64 (5), p.1030.e7-1030.e8

2004

Volltextzugriff (PDF)

Injectable neuromodulatory agents: botulinum toxin therapy

Urologic clinics of North America, 2005-02, Vol.32 (1), p.89-99

2005

Volltextzugriff (PDF)

Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

European urology supplements : official journal of the European Association of Urology, 2019-03, Vol.18 (1), p.e758-e759

2019

Volltextzugriff (PDF)

571 - Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

European urology supplements : official journal of the European Association of Urology, 2019-03, Vol.18 (1), p.e758-e759

2019

Volltextzugriff (PDF)

Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052

European urology supplements : official journal of the European Association of Urology, 2018-03, Vol.17 (2), p.e124-e125

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Understanding Mid For Micturition Frequency, A Pivotal Endpoint For Oab Studies

Perioperative use of etoricoxib in patients undergoing total abdominal hysterectomy

P83.02 Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

Once Daily Vibegron Improves Quality of Life Measures in Patients with Overactive Bladder

PUK17 - Once Daily Vibegron Improves Quality of Life Measures in Patients with Overactive Bladder

T624 RELATIVE TREATMENT EFFECTS OF PERIOPERATIVE ETORICOXIB ON PAIN AT REST AND UPON MOVEMENT FOLLOWING ABDOMINAL HYSTERECTOMY

PUK27 - Understanding Mid For Micturition Frequency, A Pivotal Endpoint For Oab Studies

Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

Bladder dysfunction in mice with experimental autoimmune encephalomyelitis

Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study

989TiPKEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

988TiPKEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)

990TiPPhase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy

919PThree-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

864OPembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

Results of a Simplified Technique for Buried Penis Repair

901PImpact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Pelvic hematoma as a cause of bladder perforation and gross hematuria

Injectable neuromodulatory agents: botulinum toxin therapy

Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

571 - Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052

Suchergebnisse filtern